The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegromab, brensocatib and diazoxide choline.
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products
The European Medicines Agency is considering whether apitegromab, brensocatib and diazoxide choline, from Scholar, Insmed and Soleno respectively, are drugs that are of potential major public health interest, particularly from the point of view of therapeutic innovation.
More from EU CHMP
• By
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
• By
Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.
• By
Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.
• By
The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.
More from Geography
• By
Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.
• By
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.